This eight-part webcast series on liquid biopsy titled, “Utility of Cell-free DNA in the Clinic: Current State and Future Directions.” will cover a range of concepts from the basic biological underpinnings of cell-free DNA (cfDNA) to new and specific advances (and the clinical implications thereof) in the diagnostic and prognostic use of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). These eight webcasts will occur every 2-3 months, beginning in May, 2021.
In addition to the eight hour-long webinars, a series of “Molecular in a Minute” micro-learning modules will be recorded. These will cover new topics, advances, and applications for liquid biopsy in the laboratory and in the clinic. Links coming soon.
After broadcast, each webinar and Molecular in a Minute module will be posted on the AMPEDTM online Learning Management System. Keep checking back here for additional content and information.
Following the full program, participants will be able to:
Webinar #1: Basic Biology and Detection of Cell-Free DNA
Speakers: Rena Xian, MD and Lynette M. Sholl MD
Date: Tuesday May 18th, 2021 at 2:00pm Eastern
Webinar #2: Practical Analytical and Clinical validation Strategies for Cell-Free Tumor DNA Assays
Speaker: Christina Lockwood, PhD
Date: Tuesday July 27, 2021 at 2:00pm Eastern
Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers
Speaker: Everett Moding, MD PhD
Date: Tuesday September 28, 2021 at 2:00pm Eastern
ctDNA Sequencing: A strategy for treatment response monitoring of aggressive B cell lymphoma
Description: This module will summarize the current knowledge related to circulating tumor DNA in patients with aggressive B cell lymphoma, such as diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and discuss how ctDNA measurements can be used to monitor treatment response in the front-line setting.
Speaker: Rena Xian, MD
Length: 13 min
Recorded: May 18, 2021
How Accurate is That Test? Quality Assessment for Cell-Free DNA Tumor Tests
Description: This module summarizes laboratory error detection and reviews current quality monitoring for clinical laboratories performing cell-free tumor DNA tests.
Speaker: Christina Lockwood, MD
Length: 15 min
Recorded: July 21, 2021
Choosing the best circulating tumor DNA assay for your clinical application: technical and analytical considerations
Description: Dr. Moding discusses the fundamental differences between currently available circulating tumor DNA assays to help clinicians choose the best assay for their application.
Speaker: Everett Moding, MD
Length: 8 min
Recorded: September 23, 2021
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live to enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM (1.00 CE for each webinar). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Laboratory Education (CMLE)
This activity has been planned and implemented in accordance with the Amedco and joint provider-ship of the ASC and the Association for Molecular Pathology (AMP). Course number 7013.
This webinar series on Utility of Cell-Free DNA in the Clinic is planned and coordinated by the Liquid Biopsy Content Committee:
Rena Xian, MD, Content Chair
Marjorie Parker David, MD, MS
Margaret L. Gulley, MD
And supported by the AMP Training & Education Committee (Nathanael G. Bailey, MD, Chair)
Supported by an educational grant from AstraZeneca
Instructions for Accessing Live and On-Demand Webinars from AMP (PDF)